Cost-effectiveness analysis favors epoetin alfa to front-loaded regimens of darbepoetin alfa and dominates every other week dosing of darbepoetin alfa.

被引：0
|
作者：
Frame, D
Fastenau, JM
Piech, CT
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Dept Pharm, Chicago, IL USA
[2] Ortho Biotech Prod LP, Clin Affairs, Bridgewater, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5776
引用
收藏
页码：511B / 511B
页数：1
相关论文
共 50 条
  • [31] Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia - Results of a combined analysis
    Mirtsching, B
    Charu, V
    Vadhan-Raj, S
    Colowick, AB
    Rossi, G
    Tomita, D
    McGuire, WP
    ONCOLOGY-NEW YORK, 2002, 16 (10): : 31 - 36
  • [32] Cost and effectiveness of darbepoetin ALFA administered every 3 weeks (Q3W DA) compared with weekly epoetin ALFA (QW EA) or epoetin beta (QW EB) in patients (PTS) with chemotherapy-induced anemia (CIA): A retrospective study
    Coiffier, Bertrand
    Schlag, Rudolf
    Velasco, Amalia
    Yao, Bin
    Schupp, Marco
    Demarteau, Nadia
    Annemans, Lieven
    ANNALS OF ONCOLOGY, 2006, 17 : 293 - 293
  • [33] Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA).
    Rearden, TP
    Charu, V
    Saidman, B
    Ben-Jacob, A
    Justice, GR
    Manaim, AS
    Tomita, D
    Rossi, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 745S - 745S
  • [34] Darbepoetin alfa 200 mcg every 2 weeks (Q2W) and epoetin alfa 40,000 units every week (QW) in chemotherapy-induced anemia patients result in similar initial hemoglobin outcomes
    Patton, J
    Wallace, JF
    VALUE IN HEALTH, 2003, 6 (03) : 228 - 228
  • [35] Results of a randomized study of every three-week dosing (Q3W) of Darbepoetin alfa for chemotherapy-induced anemia (CIA).
    Rearden, T
    Charu, V
    Saidman, B
    Ben-Jacob, A
    Justice, GR
    Manaim, AS
    Katz, D
    Tomita, D
    Rossi, G
    BLOOD, 2003, 102 (11) : 20B - 21B
  • [36] Switch from weekly to every other week administration of Aranesp® (darbepoetin alfa) is effective in maintaining target haemoglobin levels in peritoneal dialysis patients
    Bajo, M. A.
    Fontan, M. Perez
    Remon, C.
    Sanchez-Tomero, J. A.
    Llados, F.
    Selgas, R.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 495 - 495
  • [37] Every-2-week (Q2W) dosing of darbepoetin alfa in patients with anemia of cancer (AOC): Interim analysis of a randomized, controlled study.
    Charu, V
    Belani, CP
    Gill, AN
    Bhatt, M
    Ben-Jacob, A
    Tomita, D
    Katz, D
    Colowick, A
    BLOOD, 2003, 102 (11) : 499A - 499A
  • [38] Aranesp™ (darbepoetin alfa) administered once every other week (Q2W) corrects anemia in patients with chronic kidney disease (CKD)
    Lindberg, JS
    Navarro, J
    Suranyi, M
    Walker, R
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) : A22 - A22
  • [39] Every-2-week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: A stratified analysis by tumor type.
    Blayney, D
    Fesen, M
    Mirtsching, BC
    Katz, D
    Tomita, D
    Colowick, A
    BLOOD, 2003, 102 (11) : 19B - 20B
  • [40] An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
    Galle, Jan-Christoph
    Claes, Kathleen
    Kiss, Istvan
    Winearls, Christopher G.
    Herlitz, Hans
    Guerin, Alain
    Di Giulio, Salvatore
    Suranyi, Michael G.
    Bridges, Ian
    Addison, Janet
    Farouk, Mourad
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2303 - 2311
12345